Cargando…

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis

OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and...

Descripción completa

Detalles Bibliográficos
Autores principales: Murata, Makoto, Suzuki, Ritsuro, Nishida, Tetsuya, Shirane, Shuichi, Shimazu, Yutaka, Minami, Yosuke, Mori, Takehiko, Doki, Noriko, Kanda, Yoshinobu, Uchida, Naoyuki, Tanaka, Masatsugu, Ishikawa, Jun, Togitani, Kazuto, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Nagamura-Inoue, Tokiko, Kiyoi, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492130/
https://www.ncbi.nlm.nih.gov/pubmed/32801269
http://dx.doi.org/10.2169/internalmedicine.4375-19
_version_ 1783582325181775872
author Murata, Makoto
Suzuki, Ritsuro
Nishida, Tetsuya
Shirane, Shuichi
Shimazu, Yutaka
Minami, Yosuke
Mori, Takehiko
Doki, Noriko
Kanda, Yoshinobu
Uchida, Naoyuki
Tanaka, Masatsugu
Ishikawa, Jun
Togitani, Kazuto
Fukuda, Takahiro
Ichinohe, Tatsuo
Atsuta, Yoshiko
Nagamura-Inoue, Tokiko
Kiyoi, Hitoshi
author_facet Murata, Makoto
Suzuki, Ritsuro
Nishida, Tetsuya
Shirane, Shuichi
Shimazu, Yutaka
Minami, Yosuke
Mori, Takehiko
Doki, Noriko
Kanda, Yoshinobu
Uchida, Naoyuki
Tanaka, Masatsugu
Ishikawa, Jun
Togitani, Kazuto
Fukuda, Takahiro
Ichinohe, Tatsuo
Atsuta, Yoshiko
Nagamura-Inoue, Tokiko
Kiyoi, Hitoshi
author_sort Murata, Makoto
collection PubMed
description OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and post-PV myelofibrosis was conducted in Japan. PATIENTS AND METHODS: Clinical data for patients with post-ET (n=29) and post-PV (n=9) myelofibrosis who had received first allogeneic HSCT were extracted from the Transplant Registry Unified Management Program, which is a registry of the outcomes of HSCT in Japan. RESULTS: Five patients died without neutrophil recovery within 60 days after transplantation. The incidence of neutrophil recovery was significantly lower in umbilical cord blood (UCB) transplantation than in related donor transplantation (40% vs. 92%, p=0.010). The 1-year non-relapse mortality for post-ET and post-PV myelofibrosis was 35% and 27%, respectively (p=0.972). No patient or transplantation characteristics were associated with non-relapse mortality. The 4-year overall survival for post-ET and post-PV myelofibrosis was 46% and 65%, respectively (p=0.362). A univariate analysis identified UCB transplantation (vs. related donor, p=0.017) and ≥10 times red blood cell transfusions before transplantation (vs. <10 times, p=0.037) as predictive of a lower overall survival. CONCLUSION: Allogeneic HSCT provides a long-term survival for at least some patients with post-ET and post-PV myelofibrosis. Further studies with more patients are required to determine the best alternative donor.
format Online
Article
Text
id pubmed-7492130
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-74921302020-09-23 Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis Murata, Makoto Suzuki, Ritsuro Nishida, Tetsuya Shirane, Shuichi Shimazu, Yutaka Minami, Yosuke Mori, Takehiko Doki, Noriko Kanda, Yoshinobu Uchida, Naoyuki Tanaka, Masatsugu Ishikawa, Jun Togitani, Kazuto Fukuda, Takahiro Ichinohe, Tatsuo Atsuta, Yoshiko Nagamura-Inoue, Tokiko Kiyoi, Hitoshi Intern Med Original Article OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and post-PV myelofibrosis was conducted in Japan. PATIENTS AND METHODS: Clinical data for patients with post-ET (n=29) and post-PV (n=9) myelofibrosis who had received first allogeneic HSCT were extracted from the Transplant Registry Unified Management Program, which is a registry of the outcomes of HSCT in Japan. RESULTS: Five patients died without neutrophil recovery within 60 days after transplantation. The incidence of neutrophil recovery was significantly lower in umbilical cord blood (UCB) transplantation than in related donor transplantation (40% vs. 92%, p=0.010). The 1-year non-relapse mortality for post-ET and post-PV myelofibrosis was 35% and 27%, respectively (p=0.972). No patient or transplantation characteristics were associated with non-relapse mortality. The 4-year overall survival for post-ET and post-PV myelofibrosis was 46% and 65%, respectively (p=0.362). A univariate analysis identified UCB transplantation (vs. related donor, p=0.017) and ≥10 times red blood cell transfusions before transplantation (vs. <10 times, p=0.037) as predictive of a lower overall survival. CONCLUSION: Allogeneic HSCT provides a long-term survival for at least some patients with post-ET and post-PV myelofibrosis. Further studies with more patients are required to determine the best alternative donor. The Japanese Society of Internal Medicine 2020-08-15 2020-08-15 /pmc/articles/PMC7492130/ /pubmed/32801269 http://dx.doi.org/10.2169/internalmedicine.4375-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Murata, Makoto
Suzuki, Ritsuro
Nishida, Tetsuya
Shirane, Shuichi
Shimazu, Yutaka
Minami, Yosuke
Mori, Takehiko
Doki, Noriko
Kanda, Yoshinobu
Uchida, Naoyuki
Tanaka, Masatsugu
Ishikawa, Jun
Togitani, Kazuto
Fukuda, Takahiro
Ichinohe, Tatsuo
Atsuta, Yoshiko
Nagamura-Inoue, Tokiko
Kiyoi, Hitoshi
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title_full Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title_fullStr Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title_full_unstemmed Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title_short Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
title_sort allogeneic hematopoietic stem cell transplantation for post-essential thrombocythemia and post-polycythemia vera myelofibrosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492130/
https://www.ncbi.nlm.nih.gov/pubmed/32801269
http://dx.doi.org/10.2169/internalmedicine.4375-19
work_keys_str_mv AT muratamakoto allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT suzukiritsuro allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT nishidatetsuya allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT shiraneshuichi allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT shimazuyutaka allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT minamiyosuke allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT moritakehiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT dokinoriko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT kandayoshinobu allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT uchidanaoyuki allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT tanakamasatsugu allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT ishikawajun allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT togitanikazuto allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT fukudatakahiro allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT ichinohetatsuo allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT atsutayoshiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT nagamurainouetokiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis
AT kiyoihitoshi allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis